Medtech innovator SigTuple has successfully raised ₹33 crore (approximately $4 million) in an extended Series C funding round, led by SIDBI Venture Capital. This round also saw participation from existing investors, including Endiya Partners, as well as notable strategic leaders from the healthcare sector.
This new funding comes on the heels of a $4.3 million Series C round in March 2023, which was spearheaded by Endiya Partners and Accel. To date, SigTuple has raised over $40 million in total.
The fresh capital will be instrumental in driving the company’s geographical expansion, broadening its product offerings, and supporting regulatory clearances. The Bengaluru-based company, founded in 2015 by Apurv Anand, Bharath Cheluvaraju, Rohit Kumar Pandey, and Tathagato Dastidar, specializes in AI-powered smart robotic microscopes designed to automate manual processes in clinical laboratories.
Since 2020, SigTuple has concentrated on its flagship product, AI100, which is now seeing substantial uptake within the Indian diagnostics market. The company has forged a distribution partnership with Horiba Medical for the South Asia region and has extended its reach to Southeast Asia, the Middle East, and North Africa. Plans are also underway for expansion into Europe and the Americas.
Notably, in September 2023, AI100 received US FDA 510(k) approval, positioning SigTuple as the third global company—and the first in India—to achieve this milestone for AI-assisted digital haematology.
